OncoCyte Corporation (OCX) Tops Q3 EPS by 32c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq set for higher open as oil prices extend declines, midterm results awaited
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts OCX Hot Sheet
Join SI Premium – FREE
OncoCyte Corporation (NASDAQ: OCX) reported Q3 EPS of ($0.81), $0.32 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $430 thousand versus the consensus estimate of $437.5 thousand.
For earnings history and earnings-related data on OncoCyte Corporation (OCX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Nebius stock climbs as investors see oversold opportunity
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
